Halozyme Therapeutics (NASDAQ:HALO) Given New $93.00 Price Target at Citizens Jmp

Halozyme Therapeutics (NASDAQ:HALO) had its price objective increased by investment analysts at Citizens Jmp from $92.00 to $93.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s target price points to a potential downside of 6.23% from the stock’s previous close.

Several other equities analysts have also weighed in on the stock. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 target price on the stock in a report on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday. Wells Fargo & Company upped their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, HC Wainwright raised their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $89.70.

Halozyme Therapeutics Trading Up 15.6%

Shares of HALO traded up $13.42 during midday trading on Friday, reaching $99.18. The company had a trading volume of 3,173,590 shares, compared to its average volume of 1,802,641. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $100.31. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The firm has a 50 day simple moving average of $75.74 and a 200-day simple moving average of $71.25. The stock has a market cap of $11.76 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 0.35 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the previous year, the company posted $1.54 EPS. The company’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts forecast that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insider Activity

In other news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $61,245,810.60. The trade was a 0.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 72,477 shares of company stock valued at $5,102,643. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $28,000. OneDigital Investment Advisors LLC purchased a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $254,000. Chase Investment Counsel Corp acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $2,035,000. Horizon Investment Services LLC acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $2,254,000. Finally, Global Retirement Partners LLC purchased a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $476,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 results: Halozyme reported adjusted EPS of $2.28, above the roughly $1.79-$1.82 consensus range, while revenue reached $481 million versus estimates of approximately $402 million. Revenue increased 48% year over year, and royalty revenue rose 50% to $308 million. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised full-year guidance: The company now expects 2026 revenue of $1.835 billion-$1.910 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the approximately $8.02 analyst consensus, signaling stronger expected profitability and growth.
• Positive Sentiment: Additional collaboration momentum: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s recurring royalty and licensing growth strategy. Halozyme Collaboration Agreements
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO from “market perform” to “outperform” with a $110 price target. HC Wainwright also raised its target from $95 to $115 and maintained a “buy” rating, implying substantial upside from the current trading level. Benzinga Analyst Actions
• Neutral Sentiment: The company’s earnings-call presentation and transcript provide additional details on the quarter, collaboration pipeline and operating outlook. Q2 2026 Earnings Presentation

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.